四川科伦药业股份有限公司关于签订募集资金监管协议的公告

Fundraising Overview - The company has issued 30 million convertible bonds at a price of 100 RMB each, raising a total of 300 million RMB, with a net amount of 298,005.40 million RMB after deducting fees [1] - The funds have been verified by KPMG, ensuring the accuracy of the fundraising process [1] Changes in Fund Usage - The company has terminated the original investment projects and adjusted the use of raised funds to focus on new projects related to the construction of intelligent infusion production lines and facility upgrades [2] - The investment allocation has been expanded, with the addition of five new sub-projects [2] Temporary Fund Usage - The company plans to use up to 1.25 billion RMB of idle funds to temporarily supplement working capital, with a repayment period not exceeding 12 months [3] Fund Management and Supervision - The company has established special accounts for the management of raised funds and signed regulatory agreements with banks and its sponsor to ensure proper fund usage [4][5] - The agreements stipulate that the sponsor will supervise the fund usage and conduct semi-annual checks [6] - The banks are required to provide monthly account statements and notify the sponsor of any significant withdrawals [7] Agreement Validity - The agreements will remain effective until all funds are fully utilized and the accounts are closed [8]